More than 20 million cancer cases were reported globally in 2020 with circa 30% or 6 million patients treated via Radiation Oncology. And yet, until now there hasn’t been an accessible way to measure or predict radiation dosage during treatment (known as radiation dosimetry). Oncologists usually only prescribe dosimeter use when treating cancers in or near critical organs.
The result? Accidental organ or tissue damage or deaths caused by radiation overdose toxicity. Furthermore, the growing use of flash therapy is significantly increasing the risks of unintended collateral damage in cancer patients. With high costs, long prep times and inaccurate technology, oncologists traditionally haven’t insisted on dosimetry use. Until now.
MOSkin has developed a revolutionary, low-cost, highly accurate real-time radiation dosimeter sensor that will make dosimetry use mainstream. Currently, about 12.5% of the Radiation Oncology field uses dosimetry. MOSkin has the potential to make this 100%. This will significantly reduce radiation overdose toxicity and protect cancer patients from harm.
The underlying technology was developed by the Centre for Medical Radiation Physics at the University of Wollongong, one of the largest centres of its type in the world.
All IP is fully patented in 80% of global markets. Successful trials have been conducted at 20 International and Australian-based Radiation Oncology Hospitals.
To find out more, register to attend Electrogenics Laboratories Ltd’s investor lunch on Friday 7 October at 12:30 pm.